Pfizer has a rich pipeline of drugs in development, at least some of which are likely to sell well.
UPS has turned away from Amazon.com and toward more profitable deliveries.
The Schwab U.S. Dividend Equity ETF offers both dividend income and growth.
If you want to be a savvy investor, you should know what this table is telling you:
|
Dividend-Paying Status Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » |
Average Annual Total Return, 1973-2025 |
|---|---|
|
Dividend growers and initiators |
10.22% |
|
Dividend payers |
9.20% |
|
No change in dividend policy |
6.87% |
|
Dividend non-payers |
4.21% |
|
Dividend shrinkers and eliminators |
(0.96%) |
|
Equal-weighted S&P 500 index |
7.74% |
Data source: Ned Davis Research and Hartford Funds.
As it starkly shows, it's hard to beat healthy and growing dividend-paying stocks if you're looking to boost your wealth over time. Here, then, are three to consider.
Image source: Getty Images.
Let's start with pharmaceutical giant Pfizer (NYSE: PFE). It's a compelling dividend payer largely because of its dividend yield -- recently a fat 6.7%. That payout is hefty in large part because the stock has averaged annual losses of about 7% over the past three years. (It's up 17% over the past year, though, as of June 4.) When a stock's price falls, its dividend yield rises, so many high-yielders have been facing some kind of struggle.
A key challenge for Pfizer has been the patent protection expiration of some of its biggest sellers. That's an issue for every pharmaceutical company, and one which they typically tackle by having a pipeline filled with promising drugs in development -- and/or by acquiring such promising drugs from other companies. Pfizer is doing both.
Pfizer's shares seem undervalued, too, with a recent forward P/E ratio of 9.0, well below the five-year average of 9.7.
United Parcel Service (NYSE: UPS) is another stock with a massive dividend yield, recently 7.7%. It, too, has posted average annual losses over the past three years, 8.6%. But as with Pfizer, there's a lot to like about UPS.
Detractors are wringing their hands over UPS's decision to cut back on the deliveries it makes for Amazon.com (NASDAQ: AMZN), but that's far from a death knell. Others see that as a smart move, because that arrangement has largely been a low-profit-margin one for UPS. The company is now focusing more on serving higher-margin customers, such as small and medium-sized businesses and the healthcare sector.
UPS' first-quarter report featured overall domestic revenue down 2.3%, while revenue per package grew 6.5%. Internationally, revenue rose by 3.8%, with revenue per package popping by 12.1%. The company's shares seem reasonably valued, with a recent forward P/E ratio of 14, a bit below the five-year average of 15. Long-term believers in the UPS plan will be paid handsomely while they wait.
My last suggestion is not exactly a stock. It's an exchange-traded fund (ETF) that trades like a stock. It's the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD), which recently yielded a solid 3.25% and parks investors' money across roughly 100 dividend payers such as Qualcomm (NASDAQ: QCOM), Texas Instruments (NASDAQ: TXN), and UnitedHealth Group (NYSE: UNH). (UPS shares were among its top 30 holdings recently, too.)
The ETF offers a compelling mix of both income and growth -- indeed, it was up nearly 20% year to date as of June 4. It's a good choice instead of investing in individual dividend payers on your own or in addition to doing so.
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,191!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,258,838!*
Now, it’s worth noting Stock Advisor’s total average return is 941% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 7, 2026.
Selena Maranjian has positions in Amazon, Pfizer, and Schwab U.S. Dividend Equity ETF. The Motley Fool has positions in and recommends Amazon, Pfizer, Qualcomm, Texas Instruments, and United Parcel Service. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.